Successful treatment with pollen extract of hematospermia in patients with xanthogranulomatous prostatitis

Antonio Luigi Pastore 1, 2, Yazan Al Salhi 1, Andrea Fuschi 1, Alessia Martoccia 1, Gennaro Velotti 1, Lorenzo Capone 1, Giorgio Bozzini 3, Natale Porta 4, Vincenzo Petrozza 4, Ester Illiano 5, Elisabetta Costantini 3, Antonio Carbone 1, 2

1 Sapienza University of Rome, Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit, Latina Italy;
2 Uroresearch, no profit Association for Research in Urology, Latina, Italy;
3 Department of Urology Mater Domini Humanitas Castellanza (VA), Italy;
4 Sapienza University of Rome, Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Pathology Unit, Latina Italy;
5 Department of Urology and Andrology, University of Perugia, Terni Italy.

Summary

Introduction: The aim of this study was to report our experience in the management of hematospermia observed in 16 patients suffering from xanthogranulomatous prostatitis.

Methods: Recurrent episodes of hematospermia were the onset symptom in all patients, and in 25% of patients it was combined with fever. All patients reported PSA value elevation and the digital rectal examination (DRE) revealed an increase of the gland size and of its consistency in all cases. In all patients, the hematospermia was treated with the oral administration of two tablets of pollen extract in a single (1 g) dose daily for 30 days.

Results: Sixteen patients were observed between 2008 and 2016, referring hematospermia, progressive lower urinary tract symptoms (LUTS), and serum PSA level increase. To exclude the prostate cancer presence all patients were submitted to transperineal TRUS guided biopsy. In all the patients complete resolution of hematospermia was achieved treatment with pollen extract. All patients were subsequently treated for LUTS (alpha-adrenergic blockers), but none reported any significant improvement of symptoms. Basing on these pieces of evidence, after 90 days of alpha-blockers therapy, all patients underwent bipolar TURP. Histological examination of resected prostatic tissue revealed in all patients the diagnosis of xanthogranulomatous prostatitis.

Conclusions: Patients with xanthogranulomatous prostatitis especially experience irritative symptoms, sometimes combined with fever or hematospermia. Hematospermia as the onset symptom has not been reported so far. The administration of the pollen extract for 30 days was associated with a complete resolution of hematospermia.

Key words: Hematospermia; Lower urinary tract symptoms; Pollen extract; Xanthogranulomatous prostatitis.

Submitted 6 October 2018, Accepted 26 January 2019

INTRODUCTION

Granulomatous prostatitis is a non-specific inflammatory process of the prostate gland, characterized by the presence of granuloma as the main histological feature (1). It is classified as: infectious granuloma, nonspecific granulomatous prostatitis, post-biopsy granuloma, and systemic granulomatous prostatitis. Rare forms of granulomatous prostatitis include sarcoidosis and xanthogranulomatous prostatitis (2). This form is histologically similar to granulomatous prostatitis, with the prominence of foamy histiocytes, which constitute the xanthomatous component. Non-specific granulomatous prostatitis and xanthogranulomatous prostatitis are likely caused by a blockage of prostatic ducts and stasis of gland secretions. The resulting epithelial disruption leads to the escape of cellular debris, bacterial toxins, prostatic secretions, including corpora amylacea, sperm and semen into the stroma, determining an intense localized inflammatory response. The most reported onset symptom is represented by irritative lower urinary tract symptoms and a raise of serum prostate-specific antigen (PSA) (3) that mimics adenocarcinoma (4). In this study we report our experience on xanthogranulomatous prostatitis observed in 16 patients.

All patients were complaining hematospermia, progressive lower urinary tract symptoms (LUTS), and increasing PSA levels. Aim of the study is to describe our successful therapeutic management of this bothering onset symptom, hematospermia, related to this rare form of prostatitis.

Patients and methods

All patients came to our attention complaining recurrent episodes of hematospermia (associated with fever in 25% of patients), that represented the onset symptom of all cases. All men suffered also from irritative LUTS, mostly characterized by urinary frequency, burning, hesitancy, and nocturia.

All patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the local Medical Ethical Committee (ASL LT CE approval n.08/163642 UROUNIV). In all patients, a PSA elevation was observed (range: 4.9-9.7 ng/mL), with a free/total ratio always greater than 20% (range: 22-36%). Digital rectal examination (DRE) revealed an increase in the gland volume and a consistency change.
with an irregular surface in all cases. The palpatory findings (peripheral nodule of hard consistency) and the serum total PSA level > 4 ng/mL lead us to suspect malignancy in all cases. All patients underwent an ultrasound-guided transperineal prostatic biopsy (12 cores) to exclude the presence of prostate cancer.

All patients were investigated for *Chlamydia trachomatis* (Ct), Ureaplasma urealyticum, Neisseria gonorrhoeae, herpes viruses (HSV 1/2) and *human papillomavirus* (HPV). In all cases the hematospermia was treated with the oral administration of two tablets of DEPROX 500® in a single dose daily, in line with previous studies, and according to the manufacturer’s instructions. Statistical analysis (Student t-test for paired samples) was performed to compare the outcomes before and after medical therapy and pre- and post-operative. The statistical analysis was done using SPSS software (version 21.0; SPSS Inc., Chicago, IL). P values < 0.05 were considered as statistically significant.

**RESULTS**

Sixteen patients were observed between 2008 and 2016, referring hematospermia, progressive lower urinary tract symptoms (LUTS), and serum PSA level increase. In all patients the hematospermia was treated with Pollen Extract (2 tabs - 1 g daily) for 30 days with complete resolution of this symptom. The DEPROX 500® treatment was well tolerated in all the analyzed patients, and no significant drug-related side-effect was reported.

In all 16 cases the results of infection tests, and the prostate biopsy to detect cancer resulted negative. The prostatic biopsy did not allow the histological diagnosis of xanthogranulomatous prostatitis due to the poor biopsy material that did not enable the histotyping of prostate tissue. Thereafter, all patients were treated for LUTS (alpha-adrenergic blockers), but none reported any significant improvement of symptoms, as revealed by IPSS questionnaire and the Qmax registered 30 days post treatment. For this reason, all the subjects were evaluated by transrectal ultrasound examination (TRUS) and urodynamics. TRUS showed a marked inhomogeneity of prostate tissue, with several hypo-echoic and hyper-vascularized areas and calcifications along the peripheral surface of the adenoma, while pressure/flow studies showed the presence of a severe bladder outlet obstruction (BOO). Basing on these evidences, after 90 days of alpha blockers therapy, all patients underwent transurethral bipolar endoscopic resection of the prostate (TURP). Mean catheterization time was 2.8 days (range: 2–4 days); in only one patient acute urinary retention 48 hours after catheter removal due to inflammatory condition (as revealed by DRE) occurred. PSA levels significantly decreased (below 2.0 ng/mL) in all patients. Functional outcomes before and after alpha blockers, pre and post TURP were evaluated by IPSS, IPSS-QoL, maximum flow rate (Qmax expressed in mL/sec), and post void residual urine volume (mL). All patients achieved normal IPSS scores and normal uroflowmetry parameters 5 weeks after surgery. The data are summarized in Table 1.

All patients submitted to TURP reported significant outcomes at the 3 months’ follow-up visit (p < 0.0001). Histological examination of resected prostatic tissue revealed in all patients the diagnosis of xanthogranulomatous prostatitis.

**DISCUSSION**

The histopathological examination of resected prostatic tissue in all our patients revealed xanthogranulomatous prostatitis with no evidence of malignancy. A non-specific granulomatous inflammation was found, the granulomas were composed of multinucleated giant cells and “xanthogranulomatous cells” (diffusely in 13 cases, focally in one patient; Figure 1). Xanthomatous histiocytes presented a small dark nuclei and abundant clear to foamy cytoplasm due to fat droplets and could be confused with prostate carcinoma. As confirmed by our case series, the final diagnosis of xanthogranulomatous prostatitis can only be achieved by histopathological examination of the prostate (7, 8). The histological feature of xanthogranulomatous prostatitis is the presence of macrophages with foamy cytoplasm “xanthomatous cells” (CD68+) in the mixed inflammatory infiltrate with multinucleated giant cells. Major study limitation was the small number of patients, and the absence of a placebo group of treatment. However, the low number of patients to be enrolled was not sufficient to design a placebo controlled study. In the present study the administration of DEPROX 500® was able to achieve the complete resolution of hematospermia with a disappearance of this onset symptom in all patients within 15 days of treatment assumption, without severe side-effects. To the best of our knowledge this was the first study to evaluate this treatment for this symptom. Furthermore, hematospermia as the onset symptom has not been reported so far. Hematospermia has been sporadically reported as an accompanying symptom in very few cases (9), but only in our case series it represented the uncommon symptom of the disease onset. In 40% of all cases reporting hematospermia, an infectious condition is revealed. Other etiologic factors are inflam-

<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Table 1.</strong> Functional outcomes before and after alpha blocker’s therapy, and preoperative and 3 months after TURP.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Before therapy</th>
<th>After therapy</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPSS (SD)</td>
<td>23.51 (0.11)</td>
<td>7.41 (0.11)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>IPSS-QoL (SD)</td>
<td>4.54 (0.03)</td>
<td>1.54 (0.05)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Qmax (SD)</td>
<td>9.69 (0.12)</td>
<td>20.74 (0.11)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PVR (SD)</td>
<td>113.09 (0.18)</td>
<td>21.12 (0.19)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PSA (SD)</td>
<td>6.24 (0.33)</td>
<td>1.32 (0.27)</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>

SD: Standard Deviation; IPSS: International Prostate Symptom Score; QoL: Quality of life; Qmax: maximum flow rate (mL/sec); PVR: post-void residual urine volume (mL); PSA: prostate specific antigen (ng/mL).
Figure 1.
A. Low-power photomicrograph showing intense inflammatory infiltrate composed of lymphocytes, plasma cells, neutrophils and xanthogranulomatous cells in prostatic tissue (magnification 10×); B. High-power photomicrograph showing xanthomatosum component of inflammatory infiltrate, composed of histiocytes with small dark nuclei and abundant clear to foamy cytoplasm (magnification 40×); C. CD68 stain showing the presence of xanthomatosum histiocytes in the prostatic stroma (magnification 40×).

Conclusions
The administration of DEPROX 500® was able to achieve the complete resolution of hematospermia with a disappearance of this onset symptom in all patients within 15 days of treatment assumption, without side-effects. Nevertheless, to completely resolve the bother symptoms of xanthogranulomatous prostatitis surgery was mandatory in all patients.

References

Correspondence
Antonio Luigi Pastore, MD, PhD (Corresponding Author) - antopast@hotmail.com
Yazan Al Salhi, MD
Andrea Faschi, MD
Alessia Martoccia, MD
Gennaro Velotti, MD
Lorenzo Capone, MD
Antonio Carbone, MD - antonio.carbone@uniroma1.it
Sapienza University of Rome, Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Urology Unit, ICOT, Latina (Italy)
Natalia Porta, MD
Vincenzo Petrozza, MD
Sapienza University of Rome, Faculty of Pharmacy and Medicine, Department of Medico-Surgical Sciences and Biotechnologies, Pathology Unit, Latina Italy
Giorgio Bozzini, MD
Department of Urology Mater Domini Humanitas Castellanza (Italy)
Elisabetta Costantini, MD
Department of Urology and Andrology, University of Perugia, Terni (Italy)